When destiny doesn't pan out : Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

Schulte, Brian C; Hwang, Caleb; Horvai, Andrew E; Olivier, Timothée

doi:10.1002/cncr.35539

Scientific article

English

When destiny doesn't pan out : Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

ContributorsSchulte, Brian C

; Hwang, Caleb

; Horvai, Andrew E; Olivier, Timothée

Published inCancer, vol. 130, no. 23, p. 4020-4024

Publication date2024-12-01

First online date2024-08-25

Keywords

HER2‐targeted therapy
US Food and Drug Administration (FDA) approval
Sarcoma
Trastuzumab deruxtecan (TDXd)

Affiliation entities

Faculté de médecine / Section de médecine clinique / Département de médecine

Citation (ISO format)

SCHULTE, Brian C et al. When destiny doesn’t pan out : Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan. In: Cancer, 2024, vol. 130, n° 23, p. 4020–4024. doi: 10.1002/cncr.35539

Article (Published version)

Identifiers

PID : unige:183969
DOI : 10.1002/cncr.35539
PMID : 39182174

Additional URL for this publicationhttps://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.35539

Journal ISSN0008-543X

33views

0downloads

Creation25/02/2025 11:02:11

First validation19/03/2025 14:04:24

Update19/03/2025 14:04:24

Status update19/03/2025 14:04:24

Last indexation19/03/2025 14:04:26

Archive ouverte UNIGE

When destiny doesn't pan out : Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan

Technical informations